The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.
Masayuki Takeda
No relevant relationships to disclose
Isamu Okamoto
No relevant relationships to disclose
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma